Search

Keep up to date with the latest news, innovations, and developments, spotlighting groundbreaking research and emerging players.

Stay informed on the latest financial trends and investment opportunities, from startups to established players.

Explore the intersection of psychedelic medicine and cultural values, diving into ethical considerations and societal impacts within this transformative field.

Navigate the complex legal and political landscape surrounding psychedelic medicine, including regulatory updates, policy changes, and advocacy efforts.

Delve into cutting-edge scientific research and breakthroughs in the field of psychedelic medicine, with a focus on understanding the mechanisms, efficacy, and safety of these substances.

Discover the therapeutic potential of psychedelic substances, examining their role in mental health, personal growth, and overall well-being.

Nov 9-11, 2023 | Miami, FL

The Premier Global Event for Psychedelics, Mental Health & Longevity

Delve into the captivating world of psychedelic medicine at Wonderland, where the frontiers of science, spirituality, and wellness converge to create an experience unlike any other.

Discover the keys to living longer while exploring the potential of humanity’s future. Wonderland brings together the latest groundbreaking research, charting trends, and investment opportunities for an experience of a lifetime.

Uncover state-of-the-art technology, evolving trends, insightful marketing strategies, and valuable opportunities designed for professionals in the mental health and brain care sector.

With this year’s Wonderland, we want to expand the conversation to take a deep dive into the intersection of these fields with psychedelic medicine, and how combining all three can lead to living not only a longer, but happier life.

The premier global conference, Wonderland is a groundbreaking event experience where visionaries and pioneers unite to explore the future of psychedelic medicine, the business of mental health and the future of longevity medicine.

Are you ready to share your passion, knowledge, and insights with a global audience of executives, researchers, and practitioners? This is your opportunity to contribute to the evolving conversation on the future of medicine showcase your unique expertise, and inspire change in the world.

Wonderland presents a one-of-a-kind opportunity for businesses and organizations to exhibit their cutting-edge products, services, and visionary solutions to a captivated audience of professionals in the mental health and psychedelic medicine fields.

We invite companies with a shared vision to submit partnership proposals and collaborate with us on this extraordinary event. By joining forces, we can create a truly unique experience for attendees, foster lasting connections, and drive the future of psychedelic healing together.

Elevate your brand’s presence in the psychedelic medicine industry with our comprehensive suite of services, tailored to captivate your audience, strengthen your market position, and foster meaningful connections within the community.

Our website provides a platform for a range of custom content, putting your message in front of the industry’s most engaged and informed audience.

Our advertising options give you the ability to target users on their desktops, mobile devices, or when they’re at one of our in-person events. You decide when and where to connect with our audience.

Our dedicated team provides passion and specialist insight across a variety of sectors and services so, whatever the challenge, the impact is guaranteed.

You’re doing the hard work of changing the world, let our team of internationally award-winning creators focus on spreading the word as far as possible and telling your story to the world.

Microdose’s events and conferences are bringing psychedelic medicine to the mainstream. Top investors, business leaders, researchers, and advocates — our events are the hub for the psychedelic renaissance.

Justin Hanka
MindBio Therapeutics

The team at Microdose are leaders in public relations activities and have successfully assisted MindBio Therapeutics to reach a global audience that we would not have been able to reach without them.

Natalie Dolphin
Wellbeing Digital Science

The Microdose team worked with us, identifying key activities we were undertaking and promoting them through its wide-ranging media connections within psychedelics, cannabis and biotech publications. The Microdose team is professional and passionate about what it does, and this was reinforced during the pandemic when it went above and beyond our agreed contract, working with us to get key messages out to the industry quickly and effectively.

Microdose X is shifting the world’s perception of psychedelic medicine, one city at a time. Join the world’s fastest-growing psychedelic network and enjoy vibrant local meetups with like-minded souls.

The Science of Psychedelics is an accredited, definitive guide to the clinical applications of entheogenic medicines, and offers a solid introduction to psychedelic-assisted therapy and “trip sitting” skills to physicians, psychologists, social workers, mental health counselors, pharmacists, and other empowered individuals. Become trained in psychedelic medicines like psilocybin, LSD, MDMA, and ketamine today.

Psychedelia is a quarterly publication examining the ever-changing realm of drug policy and efforts to bring psychedelic therapies into the mainstream. From psilocybin mushrooms to LSD to DMT, psychedelics have the potential to revolutionize mental healthcare in North America. Psychedelia will detail the journey towards acceptance of psychedelic-assisted therapies.

Microdose is a small team of people who want to help share the potential of psychedelic medicine with the world, bringing together our unique expertise and diverse backgrounds to create a platform that inspires, informs, and fosters a thriving community in this transformative field.

Our team shares a passion for psychedelic medicine and we all have a different story on how we ended up here. We want to share those stories and highlight the amazing people that help us do what we do.

Connect with our team to explore how we can collaborate and unlock the potential of psychedelic medicine together, fostering growth and innovation in this dynamic industry.

Pure Extracts Enters Into Biomass Purchase Agreements To Support Oil Extract Production

VANCOUVER, British Columbia, Jan. 25, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, is pleased to announce that it has entered into its first substantial biomass purchase agreements in order to scale-up its production of both THC and CBD extracts.

The Company has recently agreed to purchase 220 kgs of high potency THC cannabis dried flower from a large, Canadian Licenced Producer and it has also agreed to purchase 1,000 kgs of high potency CBD biomass from a top, Western Canada, cultivator. With biomass prices touching new lows, the Company believes that the timing was right for its first strategic purchases, which will drive revenue growth in Q1 2021.

The cannabis will be used to produce full spectrum (FSO) THC oil with a minimum purity of 67% and distillate with a minimum purity of 86%. The hemp will be used to produce full spectrum (FSO) CBD oil with a minimum purity of 66% and distillate with a minimum purity of 85%. From these 2 biomass purchases alone, the Company will be able to produce approximately 70 kgs of CBD distillate and 25 kgs of THC distillate. At current wholesale prices of $6,000/kg and $6,800/kg respectively, this biomass could lead to $590,000 in near term sales revenue.

Pure Extracts CEO, Ben Nikolaevsky, remarked, “Having a stockpile of biomass makes sense for us now as Pure Extracts starts to build its name in the elite category of extractors. We are looking forward to showcasing our world class products and consistently ramping-up revenue this year.”

Continue on your trip...

About Pure Extracts (CSE: PULL) (Frankfurt: PUX)
The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.

For further information please contact Empire Communications Group at (604) 343-2724.

ON BEHALF OF THE BOARD
Ben Nikolaevsky
Ben Nikolaevsky
CEO and Director

The CSE has neither approved nor disapproved the contents of this press release.

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. Financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from supply agreement recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

Learn more about the psychedelics industry at Microdose.

Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Follow us on social